{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:31:16Z","timestamp":1740133876625,"version":"3.37.3"},"reference-count":10,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"abstract":"<jats:p>We describe the novel use of oral chloramphenicol for treatment-resistant<jats:italic>Mycoplasma genitalium (M. genitalium<\/jats:italic>) infection in a 20-year-old heterosexual cisgender male presenting with recurrent symptomatic non-gonococcal urethritis.<jats:italic>M. genitalium<\/jats:italic>urethritis is an increasingly common clinical conundrum in sexual health clinics and in cases of second-line treatment failure (such as moxifloxacin), UK and international guidelines struggle to make recommendations for third-line treatments. As shown in our case, the evidence base for third-line treatments is lacking, with poor success rates, and may be poorly tolerated. Here we demonstrate the novel use of a well-tolerated oral antimicrobial, chloramphenicol, resulting in rapid microbiological and clinical cure in treatment-resistant<jats:italic>M. genitalium<\/jats:italic>urethritis.<\/jats:p>","DOI":"10.1136\/sextrans-2022-055621","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:55:11Z","timestamp":1675126511000},"page":"sextrans-2022-055621","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Novel use of oral chloramphenicol for treatment-resistant<i>Mycoplasma genitalium<\/i>"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0931-3612","authenticated-orcid":false,"given":"Jonathan Joseph","family":"Goodfellow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7750-650X","authenticated-orcid":false,"given":"Jo","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke S P","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2434-0101","authenticated-orcid":false,"given":"Michael","family":"Rayment","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"2023013016550467000_sextrans-2022-055621v1.1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv194"},{"key":"2023013016550467000_sextrans-2022-055621v1.2","unstructured":"Public Health England (PHE) . Mycoplasma genitalium antimicrobial resistance surveillance (MARS): pilot report, 2020."},{"key":"2023013016550467000_sextrans-2022-055621v1.3","doi-asserted-by":"publisher","DOI":"10.1177\/0956462419825948"},{"key":"2023013016550467000_sextrans-2022-055621v1.4","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-47-12-1115"},{"key":"2023013016550467000_sextrans-2022-055621v1.5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40121-020-00378-3","article-title":"Treatment of community-acquired pneumonia: a focus on lefamulin","volume":"10","author":"Eraikhuemen","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2023013016550467000_sextrans-2022-055621v1.6","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix132"},{"key":"2023013016550467000_sextrans-2022-055621v1.7","first-page":"169","article-title":"Antibiotic-resistant mutants of Mycoplasma pneumoniae","volume":"16","author":"Stopler","year":"1980","journal-title":"Isr J Med Sci"},{"key":"2023013016550467000_sextrans-2022-055621v1.8","doi-asserted-by":"crossref","DOI":"10.3201\/eid2808.220094","article-title":"Weighing potential benefits and harms of Mycoplasma genitalium testing and treatment approaches","volume":"28","author":"Manhart","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2023013016550467000_sextrans-2022-055621v1.9","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/OLQ.0000000000001493","article-title":"Frequency and correlates of Mycoplasma genitalium antimicrobial resistance mutations and their association with treatment outcomes: findings from a national sentinel surveillance pilot in England","volume":"48","author":"Fifer","year":"2021","journal-title":"Sex Transm Dis"},{"key":"2023013016550467000_sextrans-2022-055621v1.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1952.02930310037008"}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2022-055621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:55:20Z","timestamp":1675126520000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2022-055621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":10,"alternative-id":["10.1136\/sextrans-2022-055621"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2022-055621","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"type":"print","value":"1368-4973"},{"type":"electronic","value":"1472-3263"}],"subject":[],"published":{"date-parts":[[2023,1,30]]}}}